The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer
The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the develo...
Gespeichert in:
Veröffentlicht in: | Experimental cell research 2022-06, Vol.415 (2), p.113115-113115, Article 113115 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 113115 |
---|---|
container_issue | 2 |
container_start_page | 113115 |
container_title | Experimental cell research |
container_volume | 415 |
creator | Wu, Wenzhang Zhang, Fan Zhao, Jun He, Puyi Li, Yumin |
description | The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy. |
doi_str_mv | 10.1016/j.yexcr.2022.113115 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2644360758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482722001082</els_id><sourcerecordid>2644360758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaLZpf0Gh6NhDvNVIsq0t9BBCvyAkl-QsxtJ4V4stbyU7dP99lW7aY9FhQDzvfDyMvQOxBgHNx_36SL9cWksh5RpAAdQv2ArERlRSS_mSrYQAXWkj23P2Oue9EMIYaF6xc1UrDW2rVyze74jfNtVI8-44oKc45RDp00huhzHkMV9yH3Bbvufg-CMOC13yMI5LnOYdJTwc-SFN-UCumjPH6HkJDgPFLWUeIt9inlNJOoyO0ht21uOQ6e1zvWAPX7_cX3-vbu6-_bi-uqmcqjdzRVoq7Fzb-n4D3lPvdOdU17nySLRoqK5BdsZhD2igqxtFHXqhGgEGzUZdsA-nvmW3nwvl2Y4hOxoGjDQt2cpG6wK3tSmoOqGunJET9faQwojpaEHYJ9F2b_-Itk-i7Ul0Sb1_HrB0I_l_mb9mC_D5BFA58zFQstkFKg58SORm66fw3wG_AXoxkvs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644360758</pqid></control><display><type>article</type><title>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</title><source>Access via ScienceDirect (Elsevier)</source><creator>Wu, Wenzhang ; Zhang, Fan ; Zhao, Jun ; He, Puyi ; Li, Yumin</creator><creatorcontrib>Wu, Wenzhang ; Zhang, Fan ; Zhao, Jun ; He, Puyi ; Li, Yumin</creatorcontrib><description>The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1016/j.yexcr.2022.113115</identifier><identifier>PMID: 35341774</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Epitranscriptome ; Gastric cancer ; Immunotherapy ; m6A ; Post-transcriptional ; RNA methylation</subject><ispartof>Experimental cell research, 2022-06, Vol.415 (2), p.113115-113115, Article 113115</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</citedby><cites>FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.yexcr.2022.113115$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35341774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Wenzhang</creatorcontrib><creatorcontrib>Zhang, Fan</creatorcontrib><creatorcontrib>Zhao, Jun</creatorcontrib><creatorcontrib>He, Puyi</creatorcontrib><creatorcontrib>Li, Yumin</creatorcontrib><title>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.</description><subject>Epitranscriptome</subject><subject>Gastric cancer</subject><subject>Immunotherapy</subject><subject>m6A</subject><subject>Post-transcriptional</subject><subject>RNA methylation</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpaLZpf0Gh6NhDvNVIsq0t9BBCvyAkl-QsxtJ4V4stbyU7dP99lW7aY9FhQDzvfDyMvQOxBgHNx_36SL9cWksh5RpAAdQv2ArERlRSS_mSrYQAXWkj23P2Oue9EMIYaF6xc1UrDW2rVyze74jfNtVI8-44oKc45RDp00huhzHkMV9yH3Bbvufg-CMOC13yMI5LnOYdJTwc-SFN-UCumjPH6HkJDgPFLWUeIt9inlNJOoyO0ht21uOQ6e1zvWAPX7_cX3-vbu6-_bi-uqmcqjdzRVoq7Fzb-n4D3lPvdOdU17nySLRoqK5BdsZhD2igqxtFHXqhGgEGzUZdsA-nvmW3nwvl2Y4hOxoGjDQt2cpG6wK3tSmoOqGunJET9faQwojpaEHYJ9F2b_-Itk-i7Ul0Sb1_HrB0I_l_mb9mC_D5BFA58zFQstkFKg58SORm66fw3wG_AXoxkvs</recordid><startdate>20220615</startdate><enddate>20220615</enddate><creator>Wu, Wenzhang</creator><creator>Zhang, Fan</creator><creator>Zhao, Jun</creator><creator>He, Puyi</creator><creator>Li, Yumin</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220615</creationdate><title>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</title><author>Wu, Wenzhang ; Zhang, Fan ; Zhao, Jun ; He, Puyi ; Li, Yumin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Epitranscriptome</topic><topic>Gastric cancer</topic><topic>Immunotherapy</topic><topic>m6A</topic><topic>Post-transcriptional</topic><topic>RNA methylation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Wenzhang</creatorcontrib><creatorcontrib>Zhang, Fan</creatorcontrib><creatorcontrib>Zhao, Jun</creatorcontrib><creatorcontrib>He, Puyi</creatorcontrib><creatorcontrib>Li, Yumin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Wenzhang</au><au>Zhang, Fan</au><au>Zhao, Jun</au><au>He, Puyi</au><au>Li, Yumin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>2022-06-15</date><risdate>2022</risdate><volume>415</volume><issue>2</issue><spage>113115</spage><epage>113115</epage><pages>113115-113115</pages><artnum>113115</artnum><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35341774</pmid><doi>10.1016/j.yexcr.2022.113115</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4827 |
ispartof | Experimental cell research, 2022-06, Vol.415 (2), p.113115-113115, Article 113115 |
issn | 0014-4827 1090-2422 |
language | eng |
recordid | cdi_proquest_miscellaneous_2644360758 |
source | Access via ScienceDirect (Elsevier) |
subjects | Epitranscriptome Gastric cancer Immunotherapy m6A Post-transcriptional RNA methylation |
title | The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A16%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20N6-methyladenosine:mechanisms,%20diagnostic%20value,%20immunotherapy%20prospec-ts%20and%20challenges%20in%20gastric%20cancer&rft.jtitle=Experimental%20cell%20research&rft.au=Wu,%20Wenzhang&rft.date=2022-06-15&rft.volume=415&rft.issue=2&rft.spage=113115&rft.epage=113115&rft.pages=113115-113115&rft.artnum=113115&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1016/j.yexcr.2022.113115&rft_dat=%3Cproquest_cross%3E2644360758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644360758&rft_id=info:pmid/35341774&rft_els_id=S0014482722001082&rfr_iscdi=true |